Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Dermatology

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 496 articles:
HTML format



Single Articles


    January 2023
  1. THORLACIUS L, Alam M
    A milestone reached for lichen sclerosus trial outcome standardisation.
    Br J Dermatol. 2023 Jan 27:ljad025. doi: 10.1093.
    PubMed    


  2. MCSWEENEY SM, Bintcliffe K, Fassihi H, Sarkany R, et al
    Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
    Br J Dermatol. 2023 Jan 27:ljad012. doi: 10.1093.
    PubMed    


  3. KVIST-HANSEN A, Perez-Alos L, Al-Sofi RF, Heftdal LD, et al
    Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study.
    Br J Dermatol. 2023 Jan 27:ljad023. doi: 10.1093.
    PubMed     Abstract available


  4. SIMPSON RC, Kirtschig G, Selk A, von Seitzberg S, et al
    Core outcome domains for lichen sclerosus: a CORALS initiative consensus statement.
    Br J Dermatol. 2023 Jan 26:ljac145. doi: 10.1093.
    PubMed     Abstract available


  5. SIMPSON RC
    Safety of tralokinumab in atopic dermatitis.
    Br J Dermatol. 2023 Jan 26:ljad007. doi: 10.1093.
    PubMed    


  6. GROLLEAU C, Le Cleach L, Shourick J, Sbidian E, et al
    Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs.
    Br J Dermatol. 2023 Jan 26:ljac142. doi: 10.1093.
    PubMed    



  7. A new genetic cause for woolly hair and skin fragility.
    Br J Dermatol. 2023;188:e8.
    PubMed    



  8. Clinical trial of Oleogel-S10 (birch bark extract gel) in epidermolysis bullosa.
    Br J Dermatol. 2023;188:e4.
    PubMed    



  9. Lived experiences of patients with hidradenitis suppurativa-related pain.
    Br J Dermatol. 2023;188:e6.
    PubMed    



  10. Providing new insights into the causes of large-to-giant congenital melanocytic naevi.
    Br J Dermatol. 2023;188:e7.
    PubMed    


  11. KOGAME T, Yonekura S, Lovato P, Hirata M, et al
    Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis.
    Br J Dermatol. 2023;188:146-148.
    PubMed    


  12. STARK MS
    Deficiencies in mismatch DNA repair: providing the soil for large-to-giant congenital melanocytic naevus development.
    Br J Dermatol. 2023;188:5.
    PubMed    


  13. BERTOLD C, Martel P, Passeron T, Bahadoran P, et al
    Pigmented demodicosis presenting as lentigo maligna diagnosed by reflectance confocal microscopy.
    Br J Dermatol. 2023;188:149-150.
    PubMed    


  14. WANG H, Lin Z
    Identification of the underlying gene for Flegel disease: another 'two-hit' genodermatosis?
    Br J Dermatol. 2023;188:7-8.
    PubMed    


  15. MELLERIO JE
    EASE-y does it: Oleogel-S10 for epidermolysis bullosa wounds.
    Br J Dermatol. 2023;188:10-11.
    PubMed    


  16. OKUN MM
    The promise of personalized medicine for hidradenitis suppurativa.
    Br J Dermatol. 2023;188:3.
    PubMed    


  17. JACKSON A, Moss C, Chandler KE, Balboa PL, et al
    Biallelic TUFT1 variants cause woolly hair, superficial skin fragility and desmosomal defects.
    Br J Dermatol. 2023;188:75-83.
    PubMed     Abstract available


  18. ORENSTEIN LAV, Salame N, Siira MR, Urbanski M, et al
    Pain experiences among those living with hidradenitis suppurativa: a qualitative study.
    Br J Dermatol. 2023;188:41-51.
    PubMed     Abstract available


  19. MOSS C, Roked F, Davis PJ, Khan M, et al
    Birth incidence and outcome of harlequin ichthyosis and collodion membrane in the UK and Ireland: a national 2-year prospective surveillance study.
    Br J Dermatol. 2023;188:139-140.
    PubMed    


  20. KEARNEY N, Kirby B
    The devastating impact of hidradenitis suppurativa on employment.
    Br J Dermatol. 2023;188:9-10.
    PubMed    


  21. THACI D, Vender R, de Rie MA, Conrad C, et al
    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Br J Dermatol. 2023;188:22-31.
    PubMed     Abstract available


  22. MIRALI S, Yeung J
    Does bimekizumab stand the test of time for psoriasis?
    Br J Dermatol. 2023;188:5-6.
    PubMed    


  23. SCHNEIDER-BURRUS S, Kalus S, Fritz B, Wolk K, et al
    The impact of hidradenitis suppurativa on professional life.
    Br J Dermatol. 2023;188:122-130.
    PubMed     Abstract available


  24. ZHANG J, Schuttelaar MLA
    Water and adult eczema: the hard truth?
    Br J Dermatol. 2023;188:e1.
    PubMed    


  25. AUBERT H, Arlegui H, De Rycke Y, Bachelez H, et al
    Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
    Br J Dermatol. 2023;188:150-152.
    PubMed    


  26. WEI B, Gu J, Gao B, Bao Y, et al
    Deficient mismatch repair is detected in large-to-giant congenital melanocytic naevi: providing new insight into aetiology and diagnosis.
    Br J Dermatol. 2023;188:64-74.
    PubMed     Abstract available


  27. YUMICEBA V, Spielmann M
    When too much is too much: noncoding duplications in skin disorders.
    Br J Dermatol. 2023;188:e2-e3.
    PubMed    


  28. JAGLE S, Hsu HH, Juratli HA, Zimmer AD, et al
    Pathogenic variants in the SPTLC1 gene cause hyperkeratosis lenticularis perstans.
    Br J Dermatol. 2023;188:94-99.
    PubMed     Abstract available


  29. BROWN AC, Earp EM, Veitch D, Wernham A, et al
    The top 10 research priorities for skin cancer surgery in the UK: results of a James Lind Alliance Priority Setting Partnership.
    Br J Dermatol. 2023;188:141-142.
    PubMed    


  30. VINCENT R, Ormerod E, Gollins CE, Rai N, et al
    Semi-virtual patch testing: the future?
    Br J Dermatol. 2023;188:137-139.
    PubMed    


  31. OYMANNS M, Daum-Marzian M, Bellm A, Elsayad K, et al
    Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;188:145-146.
    PubMed    


  32. GABES M, Donhauser T, Kann G, Masur C, et al
    Burden of disease: assessing quality-of-life impacts in hyperhidrosis.
    Br J Dermatol. 2023;188:143-145.
    PubMed    


  33. SHIONOYA A, Yoto Y, Hida T, Ishikawa A, et al
    Bacillus Calmette-Guerin-induced lupus vulgaris in a patient with Mendelian susceptibility to mycobacterial disease caused by a novel STAT1 variation.
    Br J Dermatol. 2023;188:142-143.
    PubMed    


  34. HAMBLY R, Gatault S, Smith CM, Iglesias-Martinez LF, et al
    B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.
    Br J Dermatol. 2023;188:52-63.
    PubMed     Abstract available


  35. ZHOU L, Shao L, Gao S, Cui C, et al
    Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.
    Br J Dermatol. 2023;188:112-121.
    PubMed     Abstract available


  36. CLARK A, Murphy MJ, King B, Cohen JM, et al
    Patient perspectives on the lived experience of granuloma annulare.
    Br J Dermatol. 2023;188:134-136.
    PubMed    


  37. KRAKOWSKI I, Habel H, Nielsen K, Ingvar C, et al
    Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
    Br J Dermatol. 2023;188:32-40.
    PubMed     Abstract available


  38. VAN EGMOND S, de Vere Hunt I, Cai ZR, Rizk N, et al
    The perspectives of 606 US dermatologists on active surveillance for low-risk basal cell carcinoma.
    Br J Dermatol. 2023;188:136-137.
    PubMed    


  39. KERN JS, Sprecher E, Fernandez MF, Schauer F, et al
    Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
    Br J Dermatol. 2023;188:12-21.
    PubMed     Abstract available



  40. Patients with melanoma and diabetes benefit from metformin treatment.
    Br J Dermatol. 2023;188:e5.
    PubMed    


  41. FISCHER J, Alter S
    Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing.
    Br J Dermatol. 2023;188:8-9.
    PubMed    


  42. ARDERN-JONES MR, Buchanan EE, Njungu S, O'Driscoll D, et al
    Successful Dose Reduction of Dupilumab in Atopic Dermatitis.
    Br J Dermatol. 2023 Jan 20:ljad011. doi: 10.1093.
    PubMed    


  43. PADOVESE V, Fuller LC, Griffiths CEM, Maurer T, et al
    Migrant skin health - Perspectives from the Migrant Health Summit, Malta, 2022.
    Br J Dermatol. 2023 Jan 19:ljad001. doi: 10.1093.
    PubMed    


  44. MAUL JT, Frohlich F, Maul LV, Stunnenberg R, et al
    Access to psoriasis treatment in Brazil and Chile: A cross-sectional multi-centre ;Global Healthcare Study on Psoriasis.
    Br J Dermatol. 2023 Jan 19:ljac128. doi: 10.1093.
    PubMed     Abstract available


  45. BRAVO FG
    Assessing the use of biologic therapy for psoriasis in Latin America.
    Br J Dermatol. 2023 Jan 13:ljad003. doi: 10.1093.
    PubMed    


    December 2022
  46. SO C, McCarthy D, Watts CG, Kearney C, et al
    Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia.
    Br J Dermatol. 2022 Dec 22:ljac111. doi: 10.1093.
    PubMed    


  47. CICHY J
    Compartmentalized response of the human epidermis to staphylococci.
    Br J Dermatol. 2022 Dec 21:ljac125. doi: 10.1093.
    PubMed    


  48. VEGAS LP, Claudepierre P
    Trajectories of comorbidities in patients with psoriasis: a question to be answered.
    Br J Dermatol. 2022 Dec 21:ljac126. doi: 10.1093.
    PubMed    


  49. LAN J, Huang Q, Yang L, Li Y, et al
    Effects of ambient air pollution on outpatient visits for psoriasis in Wuhan, China: a time-series analysis.
    Br J Dermatol. 2022 Dec 19:ljac124. doi: 10.1093.
    PubMed     Abstract available


  50. KEZIC S, van der Molen HF
    Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention.
    Br J Dermatol. 2022 Dec 14:ljac127. doi: 10.1093.
    PubMed    


  51. YUE W, Cheng D, Sun Z, Shen Y, et al
    Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study.
    Br J Dermatol. 2022 Dec 12:ljac097. doi: 10.1093.
    PubMed     Abstract available


  52. PLATAIS C, Lalagianni N, Momen S, Ormond M, et al
    Efficacy of hydroxychloroquine in oral lichen planus: a retrospective review.
    Br J Dermatol. 2022 Dec 3:ljac113. doi: 10.1093.
    PubMed    


  53. MROWIETZ U, Augustin M
    Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization.
    Br J Dermatol. 2022;187:1007-1008.
    PubMed    



  54. A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials.
    Br J Dermatol. 2022;187:e196-e221.
    PubMed    


  55. PHILPOTT M
    Transcriptomic analysis identifies regulators of the Wnt signalling and hypoxia-inducible factor pathways as possible mediators of androgenetic alopecia.
    Br J Dermatol. 2022;187:845.
    PubMed    


  56. LAX SJ, Drucker AM
    How will brepocitinib cream compare with established treatments for mild-to-moderate eczema?
    Br J Dermatol. 2022;187:838.
    PubMed    


  57. KRIDIN K, Hammers CM
    Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid.
    Br J Dermatol. 2022;187:843-844.
    PubMed    


  58. EDEN M, Hainsworth R, Gordon LG, Epton T, et al
    On the potential beneficial effects of indoor tanning: reply from the authors.
    Br J Dermatol. 2022;187:1057-1058.
    PubMed    


  59. MIDGETTE B, Strunk A, Akilov O, Alavi A, et al
    Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.
    Br J Dermatol. 2022;187:927-935.
    PubMed     Abstract available


  60. CAPOZZA K, Vastrup A, Proctor A, Roberts A, et al
    The sound of silence: where are the voices of patients in eczema guideline development?
    Br J Dermatol. 2022;187:1005-1006.
    PubMed    


  61. REHMAN R, Haque M, Ceresnie M, Hamzavi IH, et al
    Dermatological considerations and culturally sensitive recommendations for women who wear the hijab.
    Br J Dermatol. 2022;187:1003-1004.
    PubMed     Abstract available


  62. LIU J, Chen Z, Hu L, Song Z, et al
    Three new founder mutations in Chinese patients with Nagashima-type palmoplantar keratoderma.
    Br J Dermatol. 2022;187:1043-1045.
    PubMed    


  63. VERMEER MCSC, Al-Shinnag M, Sillje HHW, Gaytan AE, et al
    A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation.
    Br J Dermatol. 2022;187:1045-1048.
    PubMed     Abstract available


  64. SILVERTHORNE CA, Bowen C, Lord J, McHugh N, et al
    A qualitative study of patients' experiences of screening for psoriatic arthritis.
    Br J Dermatol. 2022;187:1035-1037.
    PubMed    


  65. LINDQVIST PG, Epstein E, Landin-Olsson M
    On the potential beneficial effects of indoor tanning.
    Br J Dermatol. 2022;187:1057.
    PubMed    


  66. MOSTMANS Y, Smith V, Cutolo M, Melsens K, et al
    Nailfold videocapillaroscopy and serum vascular endothelial growth factor in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment.
    Br J Dermatol. 2022;187:1017-1019.
    PubMed    


  67. MATARD B, Bourrat E, Cavalie M, Chiaverini C, et al
    Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association.
    Br J Dermatol. 2022;187:1026-1028.
    PubMed     Abstract available


  68. JI-XU A, Lei DK, Worswick S, Maloney NJ, et al
    Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.
    Br J Dermatol. 2022;187:1024-1026.
    PubMed    


  69. KOPTYEV J, Strunk A, Garg A
    Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa.
    Br J Dermatol. 2022;187:1015-1017.
    PubMed    


  70. COOK MK, Perche PO, White JC, Feldman SR, et al
    Psychosocial burden of frontal fibrosing alopecia: a qualitative interview study.
    Br J Dermatol. 2022;187:1013-1015.
    PubMed    


  71. LIU Q, Tang Y, Huang Y, Wang J, et al
    Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/beta-catenin signalling pathways.
    Br J Dermatol. 2022;187:936-947.
    PubMed     Abstract available


  72. GABES M, Ragamin A, Baker A, Kann G, et al
    Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
    Br J Dermatol. 2022;187:919-926.
    PubMed     Abstract available


    November 2022
  73. HU C, Jansen PW
    Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis?
    Br J Dermatol. 2022 Nov 29:ljac105. doi: 10.1093.
    PubMed    


  74. CLAYTON K, Holbrook DJ, Vallejo A, Porter G, et al
    Skin programming of inflammatory responses to Staphylococcus aureus is compartmentalized according to epidermal keratinocyte differentiation status.
    Br J Dermatol. 2022 Nov 17:ljac088. doi: 10.1093.
    PubMed     Abstract available


  75. SCHELL SL, Cong Z, Sennett ML, Gettle SL, et al
    Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
    Br J Dermatol. 2022 Nov 17:ljac096. doi: 10.1093.
    PubMed     Abstract available


  76. ROSENO NAL, Lorup EH, Richardson C, Alarcon I, et al
    Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study.
    Br J Dermatol. 2022 Nov 11:ljac086. doi: 10.1093.
    PubMed     Abstract available


  77. WITTLICH M, Westerhausen S, Strehl B, Versteeg H, et al
    The GENESIS-UV study on ultraviolet radiation exposure levels in 250 occupations to foster epidemiological and legislative efforts to combat nonmelanoma skin cancer.
    Br J Dermatol. 2022 Nov 11:ljac093. doi: 10.1093.
    PubMed     Abstract available


  78. HE X, Shi H
    How does acral melanoma respond to immunotherapy?
    Br J Dermatol. 2022 Nov 10:ljac035. doi: 10.1093.
    PubMed    


  79. VITTRUP I, Andersen YMF, Skov L, Wu JJ, et al
    The association between atopic dermatitis, cognitive function and school performance in children and young adults.
    Br J Dermatol. 2022 Nov 3:ljac058. doi: 10.1093.
    PubMed     Abstract available



  80. Measuring the effects of treatments for capillary malformations (vascular birthmarks).
    Br J Dermatol. 2022;187:e173-e192.
    PubMed    


  81. EVRENOGLOU T
    Stratification according to disease severity can better reveal the relative effectiveness of treatments for acne vulgaris.
    Br J Dermatol. 2022;187:637-638.
    PubMed    


  82. FLEDDERUS AC, Gout HA
    A core outcome set for pressure ulcers: an important step towards standardized outcome reporting of prevention strategies.
    Br J Dermatol. 2022;187:634-635.
    PubMed    


  83. FROELUNDE AS, Vestergaard C
    Prurigo nodularis: the epidemiology of an under-recognized disease.
    Br J Dermatol. 2022;187:e171-e172.
    PubMed    


  84. GIAMARELLOS-BOURBOULIS EJ
    Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita.
    Br J Dermatol. 2022;187:e170-e171.
    PubMed    


  85. ORCHARD D
    Preventing atopic eczema: vitamin D supplementation another piece of the puzzle?
    Br J Dermatol. 2022;187:630-631.
    PubMed    


  86. HARRS C, van den Akker PC, Baardman R, Duipmans JC, et al
    The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry.
    Br J Dermatol. 2022;187:824-826.
    PubMed    


  87. CHOSIDOW O, Beylot-Barry M, Corgibet F, Jouan N, et al
    Isotretinoin: reasserting its public health value at the population level, addressing potential neuropsychiatric risk at the individual level.
    Br J Dermatol. 2022;187:831-832.
    PubMed    


  88. LOPEZ DJ, Singh A, Waidyatillake NT, Su JC, et al
    The association between domestic hard water and eczema in adults from the UK Biobank cohort study.
    Br J Dermatol. 2022;187:704-712.
    PubMed     Abstract available


  89. MALOVITSKI K, Meijers O, Cohen-Barak E, Bergman J, et al
    Heterozygous variants in the integrin subunit beta 4 gene (ITGB4) cause autosomal dominant nail dystrophy.
    Br J Dermatol. 2022;187:826-828.
    PubMed    


  90. BONTOUX C, de Masson A, Thonnart N, Ram-Wolff C, et al
    Large-cell transformation is an independent poor prognostic factor in Sezary syndrome: analysis of 117 cases.
    Br J Dermatol. 2022;187:815-817.
    PubMed    


  91. RING HC, Egeberg A, Zachariae C, Thomsen SF, et al
    Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy.
    Br J Dermatol. 2022;187:813-815.
    PubMed    


  92. MAVRANEZOULI I, Daly CH, Welton NJ, Deshpande S, et al
    A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris.
    Br J Dermatol. 2022;187:639-649.
    PubMed     Abstract available


  93. ALI S, Pham H, Waterhouse M, Baxter C, et al
    The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D-Health randomized controlled trial.
    Br J Dermatol. 2022;187:667-675.
    PubMed     Abstract available


  94. LECHNER A, Coleman S, Balzer K, Kirkham JJ, et al
    Core outcomes for pressure ulcer prevention trials: results of an international consensus study: Classification: Outcomes and qualitative research.
    Br J Dermatol. 2022;187:743-752.
    PubMed     Abstract available


  95. MARANGA A, Roche FC, Alausa M, McWilliams T, et al
    Quality of life in patients with central centrifugal cicatricial alopecia: a preliminary study.
    Br J Dermatol. 2022;187:802-804.
    PubMed     Abstract available


  96. BATAILLE P, Layese R, Claudepierre P, Paris N, et al
    Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
    Br J Dermatol. 2022;187:676-683.
    PubMed     Abstract available


  97. EL-HEIS S, D'Angelo S, Curtis EM, Healy E, et al
    Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
    Br J Dermatol. 2022;187:659-666.
    PubMed     Abstract available


  98. GREENBLATT DT, Hubbard L, Bloor C, Card D, et al
    Vitamin C concentrations in patients with epidermolysis bullosa.
    Br J Dermatol. 2022;187:808-810.
    PubMed    


  99. HUGHES O
    The need for psychological support in routine dermatological care across the UK.
    Br J Dermatol. 2022;187:778-779.
    PubMed     Abstract available


  100. GAMBICHLER T, Abu Rached N, Susok L, Becker JC, et al
    Serum neuron-specific enolase independently predicts outcomes of patients with Merkel cell carcinoma.
    Br J Dermatol. 2022;187:806-808.
    PubMed    


  101. SARASWAT N, Kumar S, Tripathy DM, Gopal MM, et al
    COVID-19-associated necrolytic acral erythema with postvaccination exacerbation in a seronegative patient.
    Br J Dermatol. 2022;187:e169.
    PubMed    


  102. BOUDREAUX BW, Pincelli TP, Bhullar PK, Patel MH, et al
    Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Br J Dermatol. 2022;187:650-658.
    PubMed     Abstract available


  103. SANGHVI AP, Miles JA, Sayed C
    Clostridium difficile infection risk in patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:800-802.
    PubMed     Abstract available


  104. MERVIS JS, Maeng MM, Kirsner RS, Wester ST, et al
    Teprotumumab as a novel treatment for pretibial myxoedema.
    Br J Dermatol. 2022;187:795-797.
    PubMed    


  105. SINGH R, Balogh EA, Senthilnathan A, Richardson IM, et al
    Fear of negative evaluation in patients with hidradenitis suppurativa is correlated with worse quality of life: an observational study.
    Br J Dermatol. 2022;187:788-790.
    PubMed    


  106. BONDS PD, Huang J, Ike J, Mukherjee E, et al
    International Classification of Diseases codes do not capture all cases of hidradenitis suppurativa in the electronic health record: a retrospective cohort.
    Br J Dermatol. 2022;187:787-788.
    PubMed    


  107. BELZER A, Silber A, Mehra S, Gilani S, et al
    Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T-DM1).
    Br J Dermatol. 2022;187:e168.
    PubMed    


  108. LEWITT TM, Mammis-Gierbolini A, Parnell M, Sarfo A, et al
    International consensus definition of disease flare in hidradenitis suppurativa.
    Br J Dermatol. 2022;187:785-787.
    PubMed    


    October 2022
  109. MIDANDER K, Werner P, Isaksson M, Wisgrill L, et al
    Cobalt nanoparticles cause allergic contact dermatitis in humans.
    Br J Dermatol. 2022 Oct 28:ljac043. doi: 10.1093.
    PubMed     Abstract available


  110. TURNER CT, Zeglinski MR, Boivin W, Zhao H, et al
    Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
    Br J Dermatol. 2022 Oct 23:ljac017. doi: 10.1093.
    PubMed     Abstract available


  111. YOTSU RR, Fuller LC, Murdoch ME, Revankar C, et al
    World Health Organization strategic framework for integrated control and management of skin-related neglected tropical diseases: what does this mean for dermatologists?
    Br J Dermatol. 2022 Oct 20:ljac031. doi: 10.1093.
    PubMed    



  112. The search for measurable predictors linked with negative health complications in psoriasis.
    Br J Dermatol. 2022;187:e158-e167.
    PubMed    


  113. TZELLOS T
    Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:462-463.
    PubMed    


  114. PANDYA AG, Ezzedine K
    Noticeability of vitiligo is in the eye of the beholder.
    Br J Dermatol. 2022;187:461-462.
    PubMed    


  115. DESSINIOTI C
    Advances in acne clinical research: a new class of topical treatment for moderate-to-severe facial acne.
    Br J Dermatol. 2022;187:455-456.
    PubMed    


  116. CUCKA B, Biglione B, Zhou L, Phillips EJ, et al
    Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system.
    Br J Dermatol. 2022;187:619-622.
    PubMed    


  117. MISERY L
    Chronic prurigo.
    Br J Dermatol. 2022;187:464-471.
    PubMed     Abstract available


  118. RENERT-YUVAL Y, Correa da Rosa J, Garcet S, Pavel AB, et al
    Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
    Br J Dermatol. 2022;187:539-547.
    PubMed     Abstract available


  119. DARRIGADE AS, Oules B, Sohier P, Jullie ML, et al
    Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: 'specific' patterns in a series of 192 patients.
    Br J Dermatol. 2022;187:615-617.
    PubMed     Abstract available


  120. POTTIER C, Eymieux S, Blanchard-Laumonnier E, Robert J, et al
    Loose anagen hair syndrome: take a closer look!
    Br J Dermatol. 2022;187:e156.
    PubMed    


  121. YUKSEL YT, Edslev SM, Janstrup AK, Goldeman MS, et al
    Colonization with Staphylococcus aureus in healthcare workers: consequences of hand eczema.
    Br J Dermatol. 2022;187:609-611.
    PubMed    


  122. TAYLOR MT, Bordeaux ZA, Deng J, Parthasarathy V, et al
    Association between prurigo nodularis and substance use disorders.
    Br J Dermatol. 2022;187:608-609.
    PubMed    


  123. RING HC, Yao Y, Maul JT, Ingram JR, et al
    The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study.
    Br J Dermatol. 2022;187:523-530.
    PubMed     Abstract available


  124. BATCHELOR JM, Gran S, Leighton P, Howells L, et al
    Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability.
    Br J Dermatol. 2022;187:548-556.
    PubMed     Abstract available


  125. DANIEL SR, Gandhi K, Anastassopoulos KP, Pandya AG, et al
    Impact of nonsegmental vitiligo on patients' health-related quality of life in the United States.
    Br J Dermatol. 2022;187:603-606.
    PubMed    


  126. KLEIN EJ, Shapiro J, Piraccini B, Cummins D, et al
    Giving a voice: dermatologists' legislative advocacy for patients with hair loss.
    Br J Dermatol. 2022;187:582-583.
    PubMed    


  127. PICARDO M, Cardinali C, La Placa M, Lewartowska-Bialek A, et al
    Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.
    Br J Dermatol. 2022;187:507-514.
    PubMed     Abstract available


  128. HAGAN PG, Bouazzi D, Nyarko G, Dartey ES, et al
    Prevalence of Hidradenitis Suppurativa in Berekum, Ghana.
    Br J Dermatol. 2022;187:586-587.
    PubMed    


    September 2022
  129. GRAU-PEREZ M, Garcia-Doval I
    Differences in cutaneous manifestations of COVID-19 during the Delta and Omicron waves revealed using the ZOE app.
    Br J Dermatol. 2022 Sep 23. doi: 10.1111/bjd.21868.
    PubMed    


  130. SIMPSON EL, Merola JF, Silverberg JI, Reich K, et al
    Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
    Br J Dermatol. 2022 Sep 9. doi: 10.1111/bjd.21867.
    PubMed     Abstract available


  131. PUIG L
    Psoriasis treatment: no more room on the summit?
    Br J Dermatol. 2022 Sep 5. doi: 10.1111/bjd.21848.
    PubMed    


  132. KIM RW, Barta K, Begolka WS, Capozza K, et al
    The quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Sep 3. doi: 10.1111/bjd.21855.
    PubMed    


  133. SIVALINGAM V, Tamber K
    Understanding the impact of life with vulval lichen sclerosus.
    Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21846.
    PubMed    


  134. LEE H, Kwon O
    Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random.
    Br J Dermatol. 2022 Sep 2. doi: 10.1111/bjd.21838.
    PubMed    



  135. Revolutionizing Atopic Dermatitis, 9-11 April 2022.
    Br J Dermatol. 2022;187:e80-e155.
    PubMed    


  136. WILSON BN, Shah R, Menzer C, Aleisa A, et al
    Consensus on the Clinical Management of Chronic Radiation Dermatitis and Radiation Fibrosis: A Delphi Survey.
    Br J Dermatol. 2022 Sep 1. doi: 10.1111/bjd.21852.
    PubMed    


  137. APFELBACHER C
    Closing a gap: an investigator global assessment for use in hidradenitis suppurativa clinical trials.
    Br J Dermatol. 2022;187:e79.
    PubMed    


  138. PAVLOVSKY M, Peled A, Sarig O, Astman N, et al
    Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence.
    Br J Dermatol. 2022;187:392-400.
    PubMed     Abstract available


  139. GOULDEN V, Ling TC, Babakinejad P, Dawe R, et al
    British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022.
    Br J Dermatol. 2022;187:295-308.
    PubMed    


  140. AARTS P, van der Zee HH
    Damage in hidradenitis suppurativa: receiving the deserved attention.
    Br J Dermatol. 2022;187:282-283.
    PubMed    


  141. FAZEL S, Paljarvi T
    Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data': reply from authors.
    Br J Dermatol. 2022;187:450-451.
    PubMed    


  142. CHANG R, Lai CC, Hung YM, Wang SI, et al
    Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data'.
    Br J Dermatol. 2022;187:450.
    PubMed    


  143. GARG A, Krueger JG
    Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies.
    Br J Dermatol. 2022;187:414-415.
    PubMed     Abstract available


  144. DI CESARE A, Nikolakis G, Kanni T, Giamarellos-Bourboulis EJ, et al
    Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study.
    Br J Dermatol. 2022;187:428-430.
    PubMed    


  145. PENNITZ A, Kinberger M, Avila Valle G, Passeron T, et al
    Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials.
    Br J Dermatol. 2022;187:309-317.
    PubMed     Abstract available


  146. MERHI R, Canu D, Barnetche T, Duchez E, et al
    Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo.
    Br J Dermatol. 2022;187:422-424.
    PubMed    


  147. KLEIN B, Treudler R, Dumann K, Boldt A, et al
    Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.
    Br J Dermatol. 2022;187:419-422.
    PubMed     Abstract available


  148. GRINNELL M, Keyes E, Diaz D, Vazquez T, et al
    Mycophenolate mofetil and methotrexate efficacy in dermatomyositis.
    Br J Dermatol. 2022;187:437-438.
    PubMed    


  149. JIANG SW, Kwock JT, Liu B, Petty AJ, et al
    High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
    Br J Dermatol. 2022;187:417-419.
    PubMed     Abstract available


  150. CHEN F, Deng D, Pan C, Yao Z, et al
    Detection and characterization of low-level mosaicism among clinically unaffected parents of 'sporadic' epidermolysis bullosa simplex cases.
    Br J Dermatol. 2022;187:441-443.
    PubMed     Abstract available


  151. FRITSCHE M, Okun M, Kirby JS
    Damage in hidradenitis suppurativa: a narrative review emphasizing the need for a novel outcome measure.
    Br J Dermatol. 2022;187:288-294.
    PubMed     Abstract available


  152. HASAN ZU, Ahmed I, Matin RN, Homer V, et al
    Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
    Br J Dermatol. 2022;187:324-337.
    PubMed     Abstract available


    August 2022
  153. KEMPF W
    Follicular T helper cells and cutaneous T-cell lymphomas.
    Br J Dermatol. 2022 Aug 31. doi: 10.1111/bjd.21839.
    PubMed    


  154. MOLHO-PESSACH V, Hartshtark S, Merims S, Lotem M, et al
    Giant congenital melanocytic nevus with a novel CUX1-BRAF fusion mutation treated with trametinib.
    Br J Dermatol. 2022 Aug 28. doi: 10.1111/bjd.21851.
    PubMed    


  155. BALAK DMW, Rissmann R
    Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave.
    Br J Dermatol. 2022 Aug 22. doi: 10.1111/bjd.21813.
    PubMed    


  156. NALDI L, Cazzaniga S
    The chicken or the egg: disentangling the relationship between smoking, alcohol consumption and psoriasis using Mendelian randomization.
    Br J Dermatol. 2022 Aug 21. doi: 10.1111/bjd.21805.
    PubMed    


  157. LIU Y, Banka S, Huang Y, Hardman-Smart J, et al
    Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol basal cell carcinoma susceptibility syndrome.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21842.
    PubMed     Abstract available


  158. LANDIS MN, Arya M, Smith S, Draelos Z, et al
    Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21826.
    PubMed     Abstract available


  159. KAWSAR A, Edwards C, Patel P, Heywood RM, et al
    Checkpoint inhibitor associated bullous cutaneous immune related adverse events: a multi-centre observational study.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21836.
    PubMed     Abstract available


  160. LEVIN NA, Rashighi M
    Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21808.
    PubMed    


  161. MCCOY K, DeSimone J
    Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumor response to PD-1 inhibitor.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21831.
    PubMed    


  162. CHRISTIANSEN AG, Carstensen O, Sommerlund M, Clausen PA, et al
    Prevalence of skin sensitisation and dermatitis among epoxy-exposed workers in the wind turbine industry.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21830.
    PubMed     Abstract available


  163. KIM RW, Barta K, Begolka WS, Capozza K, et al
    Qualitative analysis of the impact of atopic dermatitis on caregivers and the quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21828.
    PubMed    


  164. HASAN SB, Gendra R, James J, Morris D, et al
    Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa.
    Br J Dermatol. 2022 Aug 12. doi: 10.1111/bjd.21821.
    PubMed     Abstract available


  165. RANUM A, Freese R, Ramesh V, Pearson DR, et al
    Lichen sclerosus in female patients is associated with an increased risk of metabolic syndrome and cardiovascular comorbidities: A retrospective cohort review.
    Br J Dermatol. 2022 Aug 10. doi: 10.1111/bjd.21811.
    PubMed    


  166. BELL KJL, Nijsten T
    Melanoma overdiagnosis: why it matters and what can be done about it.
    Br J Dermatol. 2022 Aug 5. doi: 10.1111/bjd.21750.
    PubMed    


  167. CATALA A, Clavo Escribano P, Riera J, Martin-Ezquerra G, et al
    Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases.
    Br J Dermatol. 2022 Aug 2. doi: 10.1111/bjd.21790.
    PubMed     Abstract available


  168. FENG Y, Lu Y, Wang H
    Leucoderma secondary to wig wearing.
    Br J Dermatol. 2022;187:e64.
    PubMed     Abstract available



  169. Better understanding about the severity of disease in cutaneous T-cell lymphoma from studying immune checkpoint receptors.
    Br J Dermatol. 2022;187:e69-e76.
    PubMed    


  170. GARG A, Zema C, Kim K, Gao W, et al
    Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.
    Br J Dermatol. 2022;187:203-210.
    PubMed     Abstract available


  171. BIRABAHARAN M, Kaelber DC, Orme CM, Paravar T, et al
    Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination.
    Br J Dermatol. 2022;187:271-273.
    PubMed    


  172. LIU Y, Tan Y, Liu J, Song Z, et al
    Novel and founder variants of SERPINA12 in Chinese patients with autosomal recessive palmoplantar keratoderma.
    Br J Dermatol. 2022;187:267-270.
    PubMed     Abstract available


  173. DI RAIMONDO C, Rubio-Gonzalez B, Palmer J, Weisenburger DD, et al
    Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome.
    Br J Dermatol. 2022;187:234-243.
    PubMed     Abstract available


  174. JIANG TT, Kruglov O, Geskin L, Akilov OE, et al
    Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sezary cell phenotype.
    Br J Dermatol. 2022;187:265-267.
    PubMed     Abstract available


  175. BAE JM, Kim M, Han JH, Lee S, et al
    Preventive effect of levodopa on vitiligo development: a nationwide case-control study.
    Br J Dermatol. 2022;187:259-261.
    PubMed    


  176. RING HC, Thomsen SF
    The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa.
    Br J Dermatol. 2022;187:274.
    PubMed    


  177. YUKSEL YT, Ibler K, Agner T, Ofenloch R, et al
    Validation of the Danish version of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ).
    Br J Dermatol. 2022;187:256-258.
    PubMed    


  178. DE VERE HUNT I, Halley M, Sum K, Yekrang K, et al
    A qualitative exploration of the experiences of itch for adults living with epidermolysis bullosa.
    Br J Dermatol. 2022;187:261-263.
    PubMed    


  179. BUECHLER CR, Sagher E, Tisack A, Jacobsen G, et al
    Demographic factors and disparate outcomes in mycosis fungoides: retrospective analysis of a racially diverse 440-patient cohort from Detroit, Michigan, USA.
    Br J Dermatol. 2022;187:246-248.
    PubMed    


  180. SINGH R, Mohammed A, Senthilnathan A, Feldman SR, et al
    Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study.
    Br J Dermatol. 2022;187:250-251.
    PubMed    


  181. MORGAN CL, Thomas M, Stander S, Jabbar-Lopez ZK, et al
    Epidemiology of prurigo nodularis in England: a retrospective database analysis.
    Br J Dermatol. 2022;187:188-195.
    PubMed     Abstract available


    July 2022
  182. SCHNEIDER AM, Nelson AM
    Impaired epidermal barriers in congenital ichthyoses house a changing microbial landscape.
    Br J Dermatol. 2022 Jul 29. doi: 10.1111/bjd.21746.
    PubMed    


  183. VAN DER SCHOOT LS, Atalay S, Otero ME, Kievit W, et al
    Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21797.
    PubMed    


  184. WANG L, Rocas D, Dalle S, Sako N, et al
    Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21791.
    PubMed     Abstract available


  185. SHARIATMADARI I, Matteucci P, Barreda A, O'Toole L, et al
    Response to 'British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021': Vismodegib and indications for its use.
    Br J Dermatol. 2022 Jul 23. doi: 10.1111/bjd.21788.
    PubMed    


  186. ORMEROD AD
    Predicting the outcome of psoriasis treatment.
    Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21747.
    PubMed    


  187. VISCONTI A, Murray B, Rossi N, Wolf J, et al
    Cutaneous Manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App.
    Br J Dermatol. 2022 Jul 22. doi: 10.1111/bjd.21784.
    PubMed     Abstract available


  188. LAURENT C, Lefevre G, Kahn JE, Staumont-Salle D, et al
    Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21782.
    PubMed    


  189. NIKOLAOU V, Apalla Z, Carrera C, Fattore D, et al
    Clinical associations and classification of immune checkpoint inhibitors-induced cutaneous toxicities: A multicentric study from the EADV-Task Force of Dermatology for Cancer Patients.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21781.
    PubMed     Abstract available


  190. CHOON SE, Wright AK, Griffiths CEM, Tey KE, et al
    Incidence and prevalence of psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in Teleprimary Care (TPC(R)) clinical information system from 2010 to 2020.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21768.
    PubMed     Abstract available


  191. NAGTZAAM IF, van Leersum FS, Kouwenberg LCM, Blok MJ, et al
    STS pathogenic variants in a Dutch patient cohort clinically suspected for X-linked ichthyosis shows genetic heterogeneity.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21775.
    PubMed    


  192. MOHAMAD J, Sarig O, Beattie P, Malovitski K, et al
    A unique skin phenotype resulting from a large heterozygous deletion spanning six keratin genes.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21766.
    PubMed     Abstract available


  193. YANG N, Chen L, Shao J, Jiang F, et al
    Dupilumab with concomitant JAK inhibitor: A novel treatment strategy for atopic dermatitis with poor response to dupilumab.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21776.
    PubMed    


  194. ROCCUZZO G, Fava P, Avallone G, Aquino C, et al
    Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21772.
    PubMed    


  195. ARNOLD S, Fernando S, Rees S
    Living with Vulval Lichen Sclerosus: a qualitative interview study.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21777.
    PubMed     Abstract available


  196. FROMME M, Schneider CV, Schlapbach C, Cazzaniga S, et al
    Comorbidities in lichen planus by phenome-wide association study in two biobank population cohorts.
    Br J Dermatol. 2022 Jul 12. doi: 10.1111/bjd.21762.
    PubMed     Abstract available


  197. RUIZ GENAO DP, Carretero G, Rivera-Diaz R, Carrascosa JM, et al
    Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the Biobadaderm registry.
    Br J Dermatol. 2022 Jul 12. doi: 10.1111/bjd.21763.
    PubMed    


  198. BLAUVELT A, Kimball AB, Augustin M, Okubo Y, et al
    Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week, Double-Blinded, Placebo-Controlled, Randomised Withdrawal, Phase III Trial (OASIS-1).
    Br J Dermatol. 2022 Jul 6. doi: 10.1111/bjd.21743.
    PubMed     Abstract available



  199. British Society for Investigative Dermatology Virtual Annual Meeting, 29-31 March 2021.
    Br J Dermatol. 2022;187:e1-e63.
    PubMed    


  200. HUNT N
    Identity and psychological distress in alopecia areata.
    Br J Dermatol. 2022;187:9-10.
    PubMed    


  201. SCHUTTELAAR MLA
    A new avenue for treatment of chronic hand eczema.
    Br J Dermatol. 2022;187:7-8.
    PubMed    


  202. RAVENCROFT J, Eichenfield L
    Isotretinoin does not contribute to increased neuropsychiatric risk in the overall acne population, but risk management during treatment remains essential.
    Br J Dermatol. 2022;187:8-9.
    PubMed    


  203. PALJARVI T, McPherson T, Luciano S, Herttua K, et al
    Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data.
    Br J Dermatol. 2022;187:64-72.
    PubMed     Abstract available


  204. MACBETH AE, Holmes S, Harries M, Chiu WS, et al
    The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care.
    Br J Dermatol. 2022;187:73-81.
    PubMed     Abstract available


  205. WORM M, Thyssen JP, Schliemann S, Bauer A, et al
    The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
    Br J Dermatol. 2022;187:42-51.
    PubMed     Abstract available


  206. WANG J, Ram-Wolff C, Dobos G, Al Hage J, et al
    Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
    Br J Dermatol. 2022;187:129-131.
    PubMed    


  207. HEWITT RM, Bundy C, Newi AL, Chachos E, et al
    How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast).
    Br J Dermatol. 2022;187:82-88.
    PubMed     Abstract available



  208. Eumelanin Human Skin Colour Scale: proof-of-concept study.
    Br J Dermatol. 2022;187:vi.
    PubMed    


    June 2022
  209. WEI J, Zhu J, Xu H, Zhou D, et al
    Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21718.
    PubMed     Abstract available


  210. SANTANDREA G, Valli R, Ragazzi M, Castagnetti F, et al
    Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21715.
    PubMed    


  211. VONK J, de Wit JG, Voskuil FJ, Koldijk M, et al
    Fluorescence molecular imaging using cetuximab-800CW in cutaneous squamous cell carcinoma surgery: a proof-of-concept study.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21722.
    PubMed    


  212. SCHNEEWEISS MC, Kirchgesner J, Wyss R, Jin Y, et al
    Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study.
    Br J Dermatol. 2022 Jun 19. doi: 10.1111/bjd.21704.
    PubMed     Abstract available


  213. CALBET-LLOPART N, Combalia M, Kiroglu A, Potrony M, et al
    Common genetic variants associated with melanoma risk or naevus count in wild-type MC1R melanoma patients.
    Br J Dermatol. 2022 Jun 14. doi: 10.1111/bjd.21707.
    PubMed     Abstract available


  214. AGUILAR-DURAN S, Mee J, Popat S, Heelan K, et al
    Atezolizumab-induced linear IgA bullous dermatosis.
    Br J Dermatol. 2022 Jun 7. doi: 10.1111/bjd.21653.
    PubMed    


  215. FAN R, Leasure AC, Maisha FI, Little AJ, et al
    Thyroid disorders associated with lichen sclerosus: A case-control study in the All of Us research program.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21702.
    PubMed    


  216. BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
    Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.
    PubMed    


  217. ITO M, Kamata M, Uchida H, Egawa S, et al
    Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21701.
    PubMed    


  218. PENG C, Jian X, Xie Y, Li L, et al
    Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing.
    Br J Dermatol. 2022;186:997-1009.
    PubMed     Abstract available


  219. OFENLOCH R, Grochulska K, Mettang T, Weisshaar E, et al
    The incidence of chronic itch in patients on haemodialysis and associated factors.
    Br J Dermatol. 2022;186:1052-1054.
    PubMed    


  220. ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
    Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
    Br J Dermatol. 2022;186:1010-1025.
    PubMed     Abstract available


  221. BETTUZZI T, Hua C, Diaz E, Colin A, et al
    Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis.
    Br J Dermatol. 2022;186:1037-1039.
    PubMed    


  222. MIN MS, Kus K, Wei N, Kassamali B, et al
    Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study.
    Br J Dermatol. 2022;186:1035-1037.
    PubMed    


    May 2022
  223. THAM KC, Lefferdink R, Duan K, Lim SS, et al
    Distinct skin microbiome community structures in congenital ichthyosis.
    Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21687.
    PubMed     Abstract available


  224. SINGAL A, Mehta S
    Eumelanin Human Skin Colour Scale: a novel concept with potential for further refinement.
    Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21652.
    PubMed    


  225. MIURA H, Fujiwara S
    Successful treatment of severe subcorneal pustular dermatosis with the 308-nm ultraviolet B excimer laser.
    Br J Dermatol. 2022 May 28. doi: 10.1111/bjd.21633.
    PubMed    


  226. RICCI F, Abeni D
    Heterogeneity of reports about the impact of the COVID-19 pandemic on melanoma diagnosis.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21598.
    PubMed    


  227. OLSEN CM
    International surveillance of trends in melanoma survival: the impact of morphology.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21651.
    PubMed    


  228. HAN J, O'Neal S, Gravely A, Linos E, et al
    United States Academic Dermatologists' Attitudes Towards Active Surveillance for Basal Cell Carcinoma.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21675.
    PubMed    


  229. MARTIN-MORO F, Martin-Rubio I, Garcia-Vela JA
    TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous alphabeta T-cell lymphomas with peripheral blood involvement.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21678.
    PubMed    


  230. CORBETT M, Ramessur R, Marshall D, Acencio ML, et al
    Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21677.
    PubMed     Abstract available


  231. KAMMINGA NCW, van der Veldt AAM, Joosen MCW, de Joode K, et al
    Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
    Br J Dermatol. 2022 May 21. doi: 10.1111/bjd.21670.
    PubMed     Abstract available


  232. LANGAN EA, Kunstner A
    The gastrointestinal microbiome and psoriasis: more food for thought.
    Br J Dermatol. 2022 May 20. doi: 10.1111/bjd.21618.
    PubMed    


  233. BALAK DMW, Lambert J
    Weighing in on weight-based secukinumab dosing for psoriasis.
    Br J Dermatol. 2022 May 16. doi: 10.1111/bjd.21607.
    PubMed    


  234. PONTES FSC, Pereira GG, da Silva Santos PS, Pontes HAR, et al
    Isotretinoin and herpes simplex virus infection.
    Br J Dermatol. 2022 May 11. doi: 10.1111/bjd.21610.
    PubMed    


  235. SCHEEL CH, Rached NA, Gambichler T
    Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21591.
    PubMed    


  236. WHITEMAN DC, Olsen CM, MacGregor S, Law MH, et al
    The effect of screening on melanoma incidence and biopsy rates.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21649.
    PubMed     Abstract available


  237. COLE EF, Mustin DE, Feldman RJ
    The Effect of Race and Fitzpatrick Skin Type on Bullous Pemphigoid Disease Area Index (BPDAI) Scores.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21648.
    PubMed    


  238. CAPON F
    New genetic and clinical features of neonatal inflammatory skin and bowel disease 1.
    Br J Dermatol. 2022 May 6. doi: 10.1111/bjd.21589.
    PubMed    


  239. DISSEMOND J, Romanelli M
    Inflammatory skin diseases and wounds.
    Br J Dermatol. 2022 May 6. doi: 10.1111/bjd.21619.
    PubMed     Abstract available


  240. SCHUMMER P, Schilling B
    How representative are data from global trials on programmed death-1 blockade in melanoma?
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21621.
    PubMed    


  241. LEONARDI-BEE J, Drucker AM
    Systemic treatments for psoriasis: not another network meta-analysis!
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21601.
    PubMed    


  242. MAGIN P, Fisher K
    Body dysmorphic disorder, skin diseases and psychological morbidity: common and complex.
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21586.
    PubMed    


  243. CARRERA C, Podlipnik S
    Does acral melanoma need a distinctive prognostic staging system?
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21585.
    PubMed    


  244. BACHELEZ H
    Is heat shock protein 90 inhibition a relevant treatment strategy for psoriasis?
    Br J Dermatol. 2022;186:771-772.
    PubMed    


  245. BAARDMAN R, Bolling MC
    The importance of accurate epidemiological data of epidermolysis bullosa.
    Br J Dermatol. 2022;186:765-766.
    PubMed    


  246. KLEIN TM
    Content validity of five single-item instruments in adolescents with alopecia areata.
    Br J Dermatol. 2022;186:763-764.
    PubMed    



  247. Findings from a survey about hidradenitis suppurativa in the Netherlands.
    Br J Dermatol. 2022;186:e200-e219.
    PubMed     Abstract available


  248. KEARNEY N, Kirby B
    The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed.
    Br J Dermatol. 2022;186:767-768.
    PubMed    


  249. SIBBALD C, Alhusayen R
    Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox.
    Br J Dermatol. 2022;186:768-769.
    PubMed    


  250. ALAVI A, Hamzavi I, Brown K, Santos LL, et al
    Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
    Br J Dermatol. 2022;186:803-813.
    PubMed     Abstract available


  251. CHEN CW, Wei JC
    Response to 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes'.
    Br J Dermatol. 2022;186:910-911.
    PubMed    


  252. GOLDENBERG M, Krishna SG, Milani-Nejad N, Trinidad JC, et al
    Response to: 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9(th) and 10(th) Revision codes': reply from the authors.
    Br J Dermatol. 2022;186:911.
    PubMed    


  253. WONGVIBULSIN S, Parthasarathy V, Pahalyants V, Murphy W, et al
    Latent class analysis identification of prurigo nodularis comorbidity phenotypes.
    Br J Dermatol. 2022;186:903-905.
    PubMed    


  254. PETROF G, Papanikolaou M, Martinez AE, Mellerio JE, et al
    The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database.
    Br J Dermatol. 2022;186:843-848.
    PubMed     Abstract available


  255. BARRANCA A, Debarbieux S, Tancrede-Bohin E, Saillard C, et al
    A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features.
    Br J Dermatol. 2022;186:899-902.
    PubMed    


  256. YATSUZUKA K, Murakami M
    Response to 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)'.
    Br J Dermatol. 2022;186:908.
    PubMed    


  257. CRO S, Smith CH
    Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors.
    Br J Dermatol. 2022;186:909-910.
    PubMed     Abstract available


  258. MACEY J, Kitchen H, Aldhouse NVJ, Edson-Heredia E, et al
    A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
    Br J Dermatol. 2022;186:849-860.
    PubMed     Abstract available


  259. WAKKEE M
    Polygenic risk scores for melanoma: a stepwise process towards clinical implementation.
    Br J Dermatol. 2022;186:768.
    PubMed    


    April 2022
  260. FLOREZ ID
    Clinical practice guidelines for psoriasis: which ones are the best?
    Br J Dermatol. 2022 Apr 29. doi: 10.1111/bjd.21605.
    PubMed    


  261. SAMIMI M
    Is 5-fluorouracil the best candidate for topical chemoprevention of skin cancers in organ transplant recipients?
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21602.
    PubMed    


  262. ZHUANG K, Ran Y
    Primary cutaneous nocardiosis caused by a novel Nocardia species.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21599.
    PubMed    


  263. CHOON SE, Bachelez H
    Time to accurately determine the burden of generalized pustular psoriasis at the population level.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21588.
    PubMed    


  264. LEMMENS VEPP, Louwman MWJ
    Basal cell carcinoma, an often unjustly overlooked healthcare challenge.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21587.
    PubMed    


  265. BIEBER T, Reich K, Paul C, Tsunemi Y, et al
    Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Control
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21630.
    PubMed     Abstract available


  266. RAMESSUR R, Corbett M, Marshall D, Acencio ML, et al
    Biomarkers of disease progression in people with psoriasis: a scoping review.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21627.
    PubMed     Abstract available


  267. LAQUER V, Parra V, Lacour JP, Takahashi H, et al
    IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21631.
    PubMed    


  268. JENDOUBI F, Shourik J, Seneschal J, Giordano-Labadie F, et al
    Longer Dupilumab Dosing Intervals in Adult Patients with Atopic Dermatitis: Experience from a French Multicentre Retrospective Cohort Study.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21628.
    PubMed    


  269. KWAN Z, Anand RL, Mallipeddi R, Ali FR, et al
    The utility of negative histopathological analysis of debulk specimens during Mohs micrographic surgery for basal cell carcinoma.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21613.
    PubMed    


  270. GRIFFIN LR, Ryan S, Ramsay B
    Response to 'Patients with nodular prurigo commonly have pre-existing psychological disease that requires treatment concomitant with cutaneous therapies'.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21616.
    PubMed    


  271. REICH K, Cullen E, Weinberg M
    Maintenance of response in moderate-to-severe psoriasis after withdrawal of the IL-17A and IL-17F nanobody sonelokimab - Is there a role for IL-17F in disease reoccurrence?
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21617.
    PubMed    


  272. SIMPSON EL, Bissonnette R, Paller AS, King B, et al
    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): A Clinical Outcome Measure for the Severity of Atopic Dermatitis.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21615.
    PubMed     Abstract available


  273. SOLIMAN YS, Mieczkowska K, Zhu TR, Hossain O, et al
    Characterizing Basal Cell Carcinoma in Hispanic Individuals Undergoing Mohs Micrographic Surgery: A 7-year Retrospective Review at an Academic Institution in the Bronx.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21614.
    PubMed    


  274. MANOLACHE L, Finlay AY
    Should self-help interventions become routine in psoriasis therapy?
    Br J Dermatol. 2022 Apr 19. doi: 10.1111/bjd.21584.
    PubMed    


  275. MAKINO T, Sugiyama H, Oshima M, Mizawa M, et al
    Cutaneous gnathostomiasis caused by Gnathostoma spinigerum.
    Br J Dermatol. 2022 Apr 15. doi: 10.1111/bjd.21007.
    PubMed    


  276. HARVIMA IT, Harvima RJ
    Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new 'revolutionary' therapeutics?
    Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21583.
    PubMed    


  277. GJERSVIK P
    The future is hard to predict, even for patients with cutaneous squamous cell carcinoma.
    Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21291.
    PubMed    


  278. BLOME C, von Stulpnagel CC, Augustin M, Mrowietz U, et al
    Measuring patient-relevant benefits in psoriasis with the Patient Benefit Index: Development and preliminary validation of a 10-item short form.
    Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21593.
    PubMed    


  279. NIELSEN ML, Nymand LK, Thomsen SF, Thyssen JP, et al
    Delay in diagnosis and treatment of patients with psoriasis - a population-based cross-sectional study.
    Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21594.
    PubMed    


  280. LOFT N, Skov L, Richardson C, Trivedi V, et al
    A nationwide population-based cohort study of the incidence of severe and rare infections among adults with psoriasis in Denmark.
    Br J Dermatol. 2022 Apr 5. doi: 10.1111/bjd.21595.
    PubMed     Abstract available


  281. NALDI L
    Going global with assessing the acne burden: is the evidence worth the effort?
    Br J Dermatol. 2022;186:605.
    PubMed    



  282. Revolutionizing Atopic Dermatitis, 11-13 December 2021.
    Br J Dermatol. 2022;186:e135-e185.
    PubMed    


  283. BARBAROT S
    Targeting the itch-scratch vicious circle in atopic eczema.
    Br J Dermatol. 2022;186:608.
    PubMed    


  284. SUBRAMANIAM KS, Antoniou MN, McGrath JA, Lwin SM, et al
    The potential of gene therapy for recessive dystrophic epidermolysis bullosa.
    Br J Dermatol. 2022;186:609-619.
    PubMed     Abstract available


  285. KASPERKIEWICZ M, Strong R, Mead K, Yale M, et al
    COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
    Br J Dermatol. 2022;186:737-739.
    PubMed    


  286. LUCKY AW, Pope E
    Pregnancy in epidermolysis bullosa: long-awaited guidelines of care.
    Br J Dermatol. 2022;186:602-603.
    PubMed    


  287. SARKANY RPE, Canfield M, Morgan M, Foster L, et al
    Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour.
    Br J Dermatol. 2022;186:713-720.
    PubMed     Abstract available


  288. GAMBICHLER T, Hamdani N, Budde H, Sieme M, et al
    Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies.
    Br J Dermatol. 2022;186:728-731.
    PubMed    


  289. CHEN H, Zhang TC, Yin XL, Man JY, et al
    Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019.
    Br J Dermatol. 2022;186:673-683.
    PubMed     Abstract available


  290. RAMIREZ-GARCIALUNA JL, Wang SC, Yangzom T, Piguet V, et al
    Use of thermal imaging and a dedicated wound-imaging smartphone app as an adjunct to staging hidradenitis suppurativa.
    Br J Dermatol. 2022;186:723-726.
    PubMed    


  291. RASHID H, Meijer JM, Bolling MC, Horvath B, et al
    Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid.
    Br J Dermatol. 2022;186:721-723.
    PubMed    


  292. CHEN XQ, Zheng DY, Xiao YY, Dong BL, et al
    Aetiology of tinea capitis in China: a multicentre prospective study.
    Br J Dermatol. 2022;186:705-712.
    PubMed     Abstract available


  293. GREENBLATT DT, Pillay E, Snelson K, Saad R, et al
    Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline.
    Br J Dermatol. 2022;186:620-632.
    PubMed    


    March 2022
  294. DADZIE OE, Sturm RA, Fajuyigbe D, Petit A, et al
    The Eumelanin Human Skin Colour Scale: A Proof-of-Concept Study.
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21277.
    PubMed     Abstract available


  295. KATO J, Namikawa K, Uehara J, Nomura M, et al
    Prognoses of melanoma patients who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: A multicenter retrospective study.
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21276.
    PubMed    


  296. DI CARLO V, Stiller CA, Eisemann N, Bordoni A, et al
    Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21274.
    PubMed     Abstract available


  297. SOWTER P, Santibanez-Koref M, Jackson MS, Borthwick GM, et al
    Response to 'Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours'.
    Br J Dermatol. 2022 Mar 24. doi: 10.1111/bjd.20970.
    PubMed    


  298. FISCHER K, Aringer M, Steininger J, Heil J, et al
    Improvement of cutaneous inflammation and panniculitis in dermatomyositis patients by the JAK-inhibitor baricitinib.
    Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21252.
    PubMed    


  299. KURTANSKY NR, Manci RN, Bello DM, Adamson AS, et al
    Risk of non-acral cutaneous melanoma after the diagnosis of acral melanoma.
    Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21251.
    PubMed    


  300. STEFANOVIC N, Fitzmaurice CJ, Ormond P, Irvine AD, et al
    Risk Factors for Distant Metastasis in Cutaneous Squamous Cell Carcinoma.
    Br J Dermatol. 2022 Mar 22. doi: 10.1111/bjd.21250.
    PubMed    


  301. BAI X, Shoushtari AN, Betof Warner A, Si L, et al
    Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study.
    Br J Dermatol. 2022 Mar 16. doi: 10.1111/bjd.21241.
    PubMed     Abstract available


  302. JACOBY TV, Otto TS, Asdourian MS, Shah N, et al
    Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243.
    PubMed    


  303. TODBERG T, Egeberg A, Zachariae C, Sorensen N, et al
    Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21245.
    PubMed     Abstract available


  304. REID C, Welsh C, Martin-Smith H, Dharmaprasad S, et al
    A Rapid Access Clinic for Psoriasis - First Experiences.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21242.
    PubMed    


  305. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin' :reply from authors.
    Br J Dermatol. 2022 Mar 10. doi: 10.1111/bjd.21239.
    PubMed    


  306. OYA K, Nakamura Y, Fujisawa Y, Nomura T, et al
    Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin'.
    Br J Dermatol. 2022 Mar 9. doi: 10.1111/bjd.21230.
    PubMed    


  307. KOREN J, Mburu S, Trigos D, Damiani G, et al
    Generalised pustular psoriasis: the case for rare disease and orphan designation.
    Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21231.
    PubMed    


  308. REICH K, Baraliakos X, Coates LC, Elewski B, et al
    Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis.
    Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21233.
    PubMed    


  309. XIA P, Pasquali L, Gao C, Srivastava A, et al
    miR-378a regulates keratinocyte responsiveness to IL-17A in psoriasis.
    Br J Dermatol. 2022 Mar 8. doi: 10.1111/bjd.21232.
    PubMed    


  310. ZAMAGNI F, Bucchi L, Mancini S, Crocetti E, et al
    The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.21051.
    PubMed     Abstract available


  311. NOVAK N, Cabanillas B
    Herpesvirus, serious and opportunistic infections associated with atopic dermatitis.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.20982.
    PubMed    


  312. PARAGH G
    Epidermal melanoma prognostic factors: a link to paracrine transforming growth factor-beta signalling.
    Br J Dermatol. 2022 Mar 2. doi: 10.1111/bjd.20981.
    PubMed    


  313. ZAGAR T, Hlaca N, Brajac I, Prpic-Massari L, et al
    Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
    Br J Dermatol. 2022;186:e110.
    PubMed    



  314. A comparison of the different questionnaires used to measure health-related quality of life in patients with dermatological conditions.
    Br J Dermatol. 2022;186:e111-e133.
    PubMed     Abstract available


  315. CONCHA JSS, Afarideh M, Werth VP
    Postinflammatory hyperpigmentation and erythema: new insights into the pathogenesis.
    Br J Dermatol. 2022;186:390-391.
    PubMed    


  316. LAYTON AM, McDonald BS, Mohd Mustapa MF, Levell NJ, et al
    National Institute for Health and Care Excellence (NICE) acne guideline: what's the latest for dermatologists?
    Br J Dermatol. 2022;186:426-428.
    PubMed    


  317. DOBOS G, Assaf C
    Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications.
    Br J Dermatol. 2022;186:387-388.
    PubMed    


  318. AOKI V, Miyamoto D
    Unfolding the worldwide incidence of bullous pemphigoid: what are we missing?
    Br J Dermatol. 2022;186:386-387.
    PubMed    


  319. SABROE RA, Lawlor F, Grattan CEH, Ardern-Jones MR, et al
    British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.
    Br J Dermatol. 2022;186:398-413.
    PubMed    


  320. GOLDENBERG M, Amigo M, Krishna SG, Milani-Nejad N, et al
    Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes.
    Br J Dermatol. 2022;186:583-585.
    PubMed    


  321. TISACK A, Fotouhi A, Fidai C, Friedman BJ, et al
    Response to 'A clinical and biological review of keratoacanthoma': reply from authors.
    Br J Dermatol. 2022;186:592-593.
    PubMed    


  322. MAZZONI D, Muir J
    Considerations in the management of keratoacanthoma.
    Br J Dermatol. 2022;186:592.
    PubMed    


  323. SIMPSON K, Low ZM, Yap T, Kern JS, et al
    Ultralow-dose rituximab in pemphigus: a single-centre experience.
    Br J Dermatol. 2022;186:581-583.
    PubMed    


  324. VELLAICHAMY G, Kohli I, Zubair R, Yin C, et al
    An in vivo model of postinflammatory hyperpigmentation and erythema: clinical, colorimetric and molecular characteristics.
    Br J Dermatol. 2022;186:508-519.
    PubMed     Abstract available


  325. BAILEY AMJ, Li HO, Burns K, Cheng W, et al
    Targeting the opioid pathway for the treatment of chronic kidney disease-associated pruritus: a systematic review and meta-analysis of randomized controlled trials.
    Br J Dermatol. 2022;186:575-577.
    PubMed    


  326. XIAO MZX, Hennessey D, Iyer A, O'Keefe S, et al
    Transcriptomic changes during stage progression of mycosis fungoides.
    Br J Dermatol. 2022;186:520-531.
    PubMed     Abstract available


  327. PERSSON MSM, Begum N, Grainge MJ, Harman KE, et al
    The global incidence of bullous pemphigoid: a systematic review and meta-analysis.
    Br J Dermatol. 2022;186:414-425.
    PubMed     Abstract available


    February 2022
  328. LEE A, Stanley G, Gardiner MD, Batchelor JM, et al
    An international clinician survey CompAring Non-Absorbable Versus Absorbable sutures for Skin surgery: the CANVAS Study.
    Br J Dermatol. 2022 Feb 22. doi: 10.1111/bjd.21062.
    PubMed    


  329. NAVRAZHINA K, Frew JW, Grand D, Williams SC, et al
    IL-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Br J Dermatol. 2022 Feb 22. doi: 10.1111/bjd.21060.
    PubMed     Abstract available


  330. MIRALI S, Fabusiwa K, Linos E
    Safety in numbers: risankizumab for moderate-to-severe psoriasis.
    Br J Dermatol. 2022 Feb 20. doi: 10.1111/bjd.20947.
    PubMed    


  331. NGUYEN R
    Ocular conjunctivitis in biological therapies for atopic dermatitis.
    Br J Dermatol. 2022 Feb 16. doi: 10.1111/bjd.20945.
    PubMed    


  332. HAN J, O'Neal S, Gravely A, Gupta R, et al
    Patients' attitudes towards active surveillance for basal cell carcinoma.
    Br J Dermatol. 2022 Feb 15. doi: 10.1111/bjd.21058.
    PubMed    


  333. TANNENBAUM R, Strunk A, Garg A
    Age- and Sex- Adjusted Prevalence Estimates Among Pediatric Patients with Psoriasis in the United States.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21057.
    PubMed    


  334. VERMEER MH, Moins-Teisserenc H, Bagot M, Quaglino P, et al
    Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardised approach.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21053.
    PubMed     Abstract available


  335. VAN COILE L, Verhaeghe E, Ongenae K, Brochez L, et al
    Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting are appropriate?
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21056.
    PubMed    


  336. YEN H, Huang CH, Huang IH, Hung WK, et al
    Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP).
    Br J Dermatol. 2022 Feb 13. doi: 10.1111/bjd.21047.
    PubMed     Abstract available


  337. SANGERS TE, Wakkee M, Kramer-Noels EC, Nijsten T, et al
    Limited impact of COVID-19 related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumor characteristics: A nationwide pathology registry analysis.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21050.
    PubMed     Abstract available


  338. MASTORINO L, Roccuzzo G, Dapavo P, Siliquini N, et al
    Patients with psoriasis resistant to multiple biologic therapies: characteristics and definition of a difficult-to-treat population.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21048.
    PubMed    


  339. EDEN M, Hainsworth R, Gordon LG, Epton T, et al
    Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21046.
    PubMed     Abstract available


  340. FUTAMURA M
    Easy assessment tool for disease severity of atopic dermatitis in clinical practice.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20951.
    PubMed    


  341. MARGOLIS DJ
    Atopic dermatitis: filaggrin and skin barrier dysfunction.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20946.
    PubMed    


  342. BECHMAN K, Cook ES, Dand N, Yiu ZZN, et al
    Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.
    Br J Dermatol. 2022 Feb 1. doi: 10.1111/bjd.21042.
    PubMed    


  343. GAO JM, Goiriz R, Rajpopat S, Goldsmith P, et al
    Occupational dermatoses during the second wave of the COVID-19 pandemic: a UK prospective study of 805 healthcare workers.
    Br J Dermatol. 2022;186:374-376.
    PubMed    



  344. Different ways of estimating the amount of individual sun exposure.
    Br J Dermatol. 2022;186:e84-e109.
    PubMed     Abstract available


  345. LEIENDECKER L, Jung PS, Obenauf AC
    Targeting CD56 with an antibody-drug conjugate in Merkel cell carcinoma.
    Br J Dermatol. 2022;186:209-210.
    PubMed    


  346. SCHELL SL, Nelson AM
    Are antimicrobial peptides a double-edged sword in hidradenitis suppurativa pathophysiology?
    Br J Dermatol. 2022;186:204-205.
    PubMed    


  347. SINCLAIR R
    Alopecia areata: progress, but who pays?
    Br J Dermatol. 2022;186:206-207.
    PubMed    


  348. VAN DER ZEE HH, van de Bunte M, van Straalen KR
    Management of mild hidradenitis suppurativa: our greatest challenge yet.
    Br J Dermatol. 2022;186:355-356.
    PubMed    


  349. GLEESON D, Cliff S, Das M
    Eruptive keratoacanthomas associated with dupilumab therapy.
    Br J Dermatol. 2022;186:376-377.
    PubMed     Abstract available


  350. NAGOBA BS, Rayate AS, Patil NR, Gavkare AM, et al
    Citric acid treatment of infected venous eczema refractory to conventional treatment: a novel approach.
    Br J Dermatol. 2022;186:377-379.
    PubMed    


  351. LEUS AJG, Horvath B, Terra JB, Diercks GFH, et al
    Eligibility criteria for programmed death receptor 1 inhibitors vs. real-world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck.
    Br J Dermatol. 2022;186:371-372.
    PubMed    


  352. GAUDIN O, Milpied B, Papouin B, Hue S, et al
    Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.
    Br J Dermatol. 2022;186:372-374.
    PubMed    


  353. CARTER C, Martin K, Gordon C, Goulding JMR, et al
    Exploring the lived experience of women with rosacea: visible difference and psychological impact.
    Br J Dermatol. 2022;186:366-367.
    PubMed    


  354. ESNAULT C, Leblond V, Martin C, Desgranges A, et al
    Adcitmer((R)) , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.
    Br J Dermatol. 2022;186:295-306.
    PubMed     Abstract available


  355. FALKENHAIN-LOPEZ D, Fulgencio-Barbarin J, Puerta-Pena M, Montero-Menarguez J, et al
    Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides.
    Br J Dermatol. 2022;186:363-365.
    PubMed    


  356. HASANAJ A, Zaki F, Harman KE, Grindlay D, et al
    Cause-specific mortality in people with bullous pemphigoid and pemphigus vulgaris: a systematic review and meta-analysis.
    Br J Dermatol. 2022;186:359-361.
    PubMed    


  357. YAO Y, Frew JW, Thomsen SF, Ring HC, et al
    Antimicrobial peptides in hidradenitis suppurativa: a systematic review.
    Br J Dermatol. 2022;186:236-244.
    PubMed     Abstract available


  358. SOUEID L, Triguero-Mas M, Dalmau A, Barrera-Gomez J, et al
    Estimating personal solar ultraviolet radiation exposure through time spent outdoors, ambient levels and modelling approaches.
    Br J Dermatol. 2022;186:266-273.
    PubMed     Abstract available


  359. HARRIES M, Macbeth AE, Holmes S, Chiu WS, et al
    The epidemiology of alopecia areata: a population-based cohort study in UK primary care.
    Br J Dermatol. 2022;186:257-265.
    PubMed     Abstract available


    January 2022
  360. PAKHCHANIAN H, Raiker R, Wolf M, Trotter SC, et al
    Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients.
    Br J Dermatol. 2022 Jan 27. doi: 10.1111/bjd.21038.
    PubMed    


  361. LAM M, Monaghan C, Chan AW, Drucker AM, et al
    Characterization of discontinuation and nonpublication of phase 3 randomized clinical trials for psoriasis.
    Br J Dermatol. 2022 Jan 21. doi: 10.1111/bjd.21025.
    PubMed    


  362. GEALE K, Schmitt-Egenolf M
    Severity of psoriasis - Time to disentangle severity from symptom control.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21023.
    PubMed    


  363. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
    PubMed    


  364. EBATA T
    Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis.
    Br J Dermatol. 2022 Jan 19:ljac082. doi: 10.1093.
    PubMed    


  365. WEI X, Wu D, Chen Y, Li H, et al
    Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21026.
    PubMed     Abstract available


  366. MUFTIN Z, Gilbert P, Thompson AR
    A Randomised Controlled Feasibility Trial of Online Compassion-focused Self-Help for Psoriasis.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21020.
    PubMed     Abstract available


  367. KOZERA E, Stewart T, Gill K, De La Vega MA, et al
    Dupilumab Associated Head and Neck Dermatitis is Associated with Elevated Pre-Treatment Serum Malassezia-Specific Immunoglobulin E: A Multicenter, Prospective Cohort Study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21019.
    PubMed    


  368. YOSIPOVITCH G, Papp K, Forman S, Han G, et al
    The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21015.
    PubMed    


  369. SCHUT C, Dalgard FJ, Bewley A, Evers AWM, et al
    Body dysmorphia in common skin diseases: Results of an observational, cross-sectional multi-centre study among dermatological out-patients in 17 European countries.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21021.
    PubMed     Abstract available


  370. SORENSEN ST, Nagy D, Lindahl LM, Farkas DK, et al
    Risk of Cancer in Patients with Psoriasis and Venous Thromboembolism: a Danish Population-based Cohort study 1996-2018.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21016.
    PubMed    


  371. SEMSARIAN CR, Ma T, Nickel B, Scolyer RA, et al
    Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
    Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21010.
    PubMed    


  372. HALLE A, De Becdelievre A, Funalot B, Labreze C, et al
    SCN10A variants associated with congenital Harlequin Syndrome.
    Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21011.
    PubMed    


  373. KODAMA S, Gupta D, Sullivan E, Rosenwasser N, et al
    Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors in children-A retrospective cohort study.
    Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20980.
    PubMed    


  374. KEZIC S, McAleer MA, Jakasa I, Goorden SMI, et al
    Children with atopic dermatitis show increased activity of beta- glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to local cytokine milieu.
    Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20979.
    PubMed     Abstract available


  375. SAMUELOV L, Sarig O, Malovitski K, Bergson S, et al
    Neonatal inflammatory skin and bowel disease type 1 caused by a complex genetic defect and responsive to combined anti-TNF-alpha and IL-12/23 blockade.
    Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20978.
    PubMed     Abstract available


  376. GINDL A, Schotta AM, Berent S, Markowicz M, et al
    Persistent Lyme disease with cutaneous borrelia biofilm formation.
    Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20977.
    PubMed    


  377. CALABRESE L, Fiocco Z, Satoh TK, Peris K, et al
    Therapeutic potential of targeting IL-1 family cytokines in chronic inflammatory skin diseases.
    Br J Dermatol. 2022 Jan 6. doi: 10.1111/bjd.20975.
    PubMed     Abstract available


  378. KEMPF W, Petrella T, Willemze R, Jansen P, et al
    Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.
    Br J Dermatol. 2022 Jan 5. doi: 10.1111/bjd.20973.
    PubMed     Abstract available


  379. ARENTS BWM, Zuuren EJV, Vermeulen S, Schoones JW, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP) - a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20972.
    PubMed     Abstract available


  380. ORMOND M, McParland H, Thakrar P, Donaldson A, et al
    Validation of an Oral Disease Severity Score for use in oral lichen planus.
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20968.
    PubMed    


  381. AUGUSTIN M, Reich K, Yamauchi P, Pinter A, et al
    Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: Results of a randomised controlled trial.
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20971.
    PubMed     Abstract available


  382. LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
    Prevalence and incidence of generalised pustular psoriasis in Sweden - a population-based register study.
    Br J Dermatol. 2022 Jan 2. doi: 10.1111/bjd.20966.
    PubMed     Abstract available


  383. MAGIN PJ, Tng ETV
    Specialists and generalists in skin disease management: educational, clinical and research imperatives.
    Br J Dermatol. 2022;186:1-2.
    PubMed    


  384. BLANCHARD G, Guenova E
    Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
    Br J Dermatol. 2022;186:15-16.
    PubMed    



  385. Psoriasis: From Gene to Clinic, 9(th) International Congress The Queen Elizabeth II Conference Centre, London, UK 9(th) -11(th) December 2021.
    Br J Dermatol. 2022;186:e2-e82.
    PubMed    


  386. NATSUGA K
    Prevention of chemotherapy-induced hair loss by peroxisome proliferator-activated receptor-gamma modulation.
    Br J Dermatol. 2022;186:14-15.
    PubMed    


  387. EZZEDINE K, Pandya AG
    British Association of Dermatologist guidelines: a lighthouse to help guide clinicians and researchers planning future clinical trials for vitiligo.
    Br J Dermatol. 2022;186:3-4.
    PubMed    


  388. FLEMING P
    Risankizumab vs. fumaric acid esters: a direct comparison.
    Br J Dermatol. 2022;186:4-5.
    PubMed    


  389. VAN STRAALEN KR, Gulliver W
    The expected missing heritability of hidradenitis suppurativa in perspective.
    Br J Dermatol. 2022;186:9-10.
    PubMed    


  390. HUGHES M, Denton CP
    The critical need for patient-reported outcome measures to assess the severity and impact of systemic sclerosis.
    Br J Dermatol. 2022;186:11-12.
    PubMed    


  391. GABES M
    The 'Chronic Itch Burden Scale': giving patients with chronic pruritus a voice.
    Br J Dermatol. 2022;186:10-11.
    PubMed    


  392. ABBAS LF, Joseph AK, Prasad S, Zhu JL, et al
    Revealing novel, latent subsets of patients with morphoea through principal component analysis.
    Br J Dermatol. 2022;186:193-195.
    PubMed    


  393. JABBOUR AJ, van Straalen KR, Colvin A, Prens EP, et al
    Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration.
    Br J Dermatol. 2022;186:183-185.
    PubMed    


  394. RAYINDA T, McSweeney SM, Dand N, Fenton DA, et al
    Clinical characteristics of male frontal fibrosing alopecia: a single-centre case series from London, UK.
    Br J Dermatol. 2022;186:195-197.
    PubMed    


  395. SIBEONI J, Dunogue B, Dupont A, Haiddar D, et al
    Development and validation of a patient-reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HAnDE) scale.
    Br J Dermatol. 2022;186:96-105.
    PubMed     Abstract available


  396. KJAERSGAARD ANDERSEN R, Clemmensen SB, Larsen LA, Hjelmborg JVB, et al
    Evidence of gene-gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins.
    Br J Dermatol. 2022;186:78-85.
    PubMed     Abstract available


  397. ELEFTHERIADOU V, Atkar R, Batchelor J, McDonald B, et al
    British Association of Dermatologists guidelines for the management of people with vitiligo 2021.
    Br J Dermatol. 2022;186:18-29.
    PubMed    


  398. THEUNIS J, Nordon C, Falissard B, Orri M, et al
    Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus.
    Br J Dermatol. 2022;186:86-95.
    PubMed     Abstract available


    December 2021
  399. MICEVIC G, Lo SN, Rajan N
    Targeting the neonatal Fc receptor in pemphigus: safety first.
    Br J Dermatol. 2021 Dec 27. doi: 10.1111/bjd.20939.
    PubMed    


  400. KAPPELIN J, Green AC, Ingvar A, Ahnlide I, et al
    Incidence and trends of basal cell carcinoma in Sweden: A population-based registry study.
    Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20964.
    PubMed     Abstract available


  401. LOBATO-BEREZO A, Gonzalez-Farre M, Pujol RM
    Pustular frontal fibrosing alopecia: a new variant within the folliculitis decalvans and lichen planopilaris phenotypic spectrum?
    Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20962.
    PubMed    


  402. PUIG L, Costanzo A, Munoz-Elias EJ, Jazra M, et al
    The biological basis of disease recurrence in psoriasis: a historical perspective and current models.
    Br J Dermatol. 2021 Dec 23. doi: 10.1111/bjd.20963.
    PubMed     Abstract available


  403. STEINBERG J, Iles MM, Lee JY, Wang X, et al
    Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20956.
    PubMed     Abstract available


  404. DANBY SG, Andrew PV, Kay LJ, Pinnock A, et al
    Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema-prone, skin.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20955.
    PubMed     Abstract available


  405. PRENS LM, Bouwman K, Troelstra LD, Prens EP, et al
    New Insights in Hidradenitis Suppurativa from a Population-based Dutch Cohort: Prevalence, Smoking Behaviour, Socioeconomic Status and Comorbidities.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20954.
    PubMed     Abstract available


  406. THOMSON J, Hogan S, Leonardi-Bee J, Williams HC, et al
    Response to 'Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments': reply from the authors.
    Br J Dermatol. 2021 Dec 17. doi: 10.1111/bjd.20950.
    PubMed    


  407. VINERETSKY KA, Domingo-Musibay E, Karagas MR, Lazovich D, et al
    A functional variant in the immune signalling receptor NKG2D alters skin cancer risk.
    Br J Dermatol. 2021 Dec 8. doi: 10.1111/bjd.20943.
    PubMed    


  408. LUENGAS-MARTINEZ A, Paus R, Young HS
    A novel personalised treatment approach for psoriasis: anti-VEGF-A therapy.
    Br J Dermatol. 2021 Dec 8. doi: 10.1111/bjd.20940.
    PubMed     Abstract available


  409. VENABLES ZC, Tokez S, Hollestein LM, Mooyaart AL, et al
    Validation of Four Cutaneous Squamous Cell Carcinoma Staging Systems Using Nationwide Data.
    Br J Dermatol. 2021 Dec 3. doi: 10.1111/bjd.20909.
    PubMed     Abstract available


  410. GUELIMI R, Afach S, Regnaux JP, Bettuzzi T, et al
    Overlapping network meta-analyses on psoriasis systemic treatments: an overview, quantity does not make quality.
    Br J Dermatol. 2021 Dec 2. doi: 10.1111/bjd.20908.
    PubMed     Abstract available



  411. Do anti-psoriatic drugs work better in women than men?
    Br J Dermatol. 2021;185:e200-e213.
    PubMed     Abstract available


  412. WOLF P
    Systemic antipsoriatic treatment: do women respond better than men and if so, why?
    Br J Dermatol. 2021;185:1088-1089.
    PubMed    


  413. KOTB I
    Evidence for the long-term efficacy and safety of guselkumab.
    Br J Dermatol. 2021;185:1087-1088.
    PubMed    


  414. ORMEROD AD
    Epidemiology, comorbidities and mortality of pyoderma gangrenosum: new insights.
    Br J Dermatol. 2021;185:1089-1090.
    PubMed    


  415. KINOSHITA-ISE M
    Refining the diagnosis and assessment methodology in frontal fibrosing alopecia.
    Br J Dermatol. 2021;185:1092-1093.
    PubMed    


  416. LEE HY
    Bullous pemphigoid: towards personalized care.
    Br J Dermatol. 2021;185:1093-1094.
    PubMed    


  417. HUFFMAN C, Cardis MA
    Image: Atypical chondrodermatitis nodularis due to in-ear headphones.
    Br J Dermatol. 2021;185:e199.
    PubMed    


  418. FINLAY AY, Griffiths TW, Belmo S, Chowdhury MMU, et al
    Why we should abandon the misused descriptor 'erythema'.
    Br J Dermatol. 2021;185:1240-1241.
    PubMed    


  419. NIKOLAKIS G, Kristandt A, Hauptmann M, Becker M, et al
    Efficacy of short-term intravenous clindamycin prior to oral clindamycin-rifampicin treatment in hidradenitis suppurativa: a retrospective case series.
    Br J Dermatol. 2021;185:1270-1272.
    PubMed    


  420. SUN H, Lim JS, Silva CF, Maczuga SA, et al
    Insurance coverage gap for treatment of melasma compared with rosacea: it pays to be light.
    Br J Dermatol. 2021;185:1252-1254.
    PubMed    


  421. WADA-IRIMADA M, Mizuashi M, Takahashi T, Tojo G, et al
    A retrospective study evaluating the outcomes of high-dose methylprednisolone pulse therapy for 483 patients with moderate-to-severe alopecia areata.
    Br J Dermatol. 2021;185:1267-1269.
    PubMed    


  422. WESTPHAL D, Garzarolli M, Sergon M, Horak P, et al
    High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
    Br J Dermatol. 2021;185:1186-1199.
    PubMed     Abstract available


  423. DOOLAN BJ, Onoufriadis A, Kantaputra P, McGrath JA, et al
    WNT10A, dermatology and dentistry.
    Br J Dermatol. 2021;185:1105-1111.
    PubMed     Abstract available


  424. THOMPSON LL, Yoon J, Chang MS, Polyakov NJ, et al
    Advanced care planning, code status and end-of-life care in patients with bullous pemphigoid.
    Br J Dermatol. 2021;185:1246-1247.
    PubMed    


  425. HEBERT V, Bastos S, Drenovska K, Meijer J, et al
    International multicentre observational study to assess the efficacy and safety of a 0.5 mg kg(-1) per day starting dose of oral corticosteroids to treat bullous pemphigoid.
    Br J Dermatol. 2021;185:1232-1239.
    PubMed     Abstract available


  426. OLSEN EA, Harries M, Tosti A, Bergfeld W, et al
    Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG).
    Br J Dermatol. 2021;185:1221-1231.
    PubMed     Abstract available


  427. BEN ABDALLAH H, Bech R, Fogh K, Olesen AB, et al
    Comorbidities, mortality and survival in patients with pyoderma gangrenosum: a Danish nationwide registry-nested case-control study.
    Br J Dermatol. 2021;185:1169-1175.
    PubMed     Abstract available


    November 2021
  428. DEAR K, Psomadakis C, Dost S, Lalagianni N, et al
    Cutaneous manifestations of PIMS-TS: a single centre experience.
    Br J Dermatol. 2021 Nov 29. doi: 10.1111/bjd.20907.
    PubMed     Abstract available


  429. SINIKUMPU SP, Huilaja L
    Challenges of multidimensional atopic dermatitis.
    Br J Dermatol. 2021 Nov 24. doi: 10.1111/bjd.20874.
    PubMed    


  430. DEZOTEUX F, El Mesbahi S, Tedbirt B, Grosjean J, et al
    Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20901.
    PubMed     Abstract available


  431. SUN MD, Kentley J, Mehta P, Duzsa S, et al
    Accuracy of commercially available smartphone applications for the detection of melanoma.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20903.
    PubMed     Abstract available


  432. CHUNG JG, Holtkamp H, Nieuwoudt M, Matthews H, et al
    The combination of Raman Spectroscopy and Mass Spectrometry to investigate cutaneous metallosis.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20902.
    PubMed     Abstract available


  433. DAND N
    Genome-wide scan for structural variation underlying psoriasis.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20836.
    PubMed    


  434. CHALMERS RJG
    Recognizing psoriasis in children and adolescents: the DIPSOC study.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20825.
    PubMed    


  435. MARUSIC Z, Calonje E
    Skin adnexal tumours in a tertiary dermatopathology service.
    Br J Dermatol. 2021 Nov 15. doi: 10.1111/bjd.20816.
    PubMed    


  436. BERGAMASCHI D
    Autophagy protects from photoageing in skin fibroblasts.
    Br J Dermatol. 2021 Nov 15. doi: 10.1111/bjd.20822.
    PubMed    


  437. PARK JH, Yoon JE, Kim YH, Kim Y, et al
    The potential skin lightening candidate, senolytic drug ABT263, for photoageing pigmentation.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20893.
    PubMed     Abstract available


  438. COSGAREA I, McConnell AT, Ewen T, Tang D, et al
    Melanoma secretion of TGFbeta-2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20889.
    PubMed     Abstract available


  439. DE VERE HUNT I, van Egmond S, Nava V, Khodosh R, et al
    Telehealth for Older Adults with Skin Disease: A Qualitative Exploration of Dermatologists' Experiences & Recommendations for Improving Care.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20891.
    PubMed     Abstract available


  440. MARNIQUET ME, Seneschal J, Darrigade AS, Staumont-Salle D, et al
    Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20883.
    PubMed     Abstract available


  441. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Risk of herpesvirus, serious, and opportunistic infections in atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20887.
    PubMed     Abstract available


  442. BREGNHOJ A, Thuesen KKH, Emmanuel T, Litman T, et al
    HSP90 inhibitor RGRN-305 for oral treatment of plaque type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20880.
    PubMed     Abstract available


  443. JABOURI H, Abbott RA
    Sustainability in skin cancer surgery.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20886.
    PubMed     Abstract available


  444. MAZZONI D, Muir J
    Response to "Interventions for basal cell carcinoma: abridged Cochrane systematic reviews and GRADE assessments".
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20878.
    PubMed     Abstract available


  445. PAPP KA, Gooderham MJ, Albrecht LE, Raymond MA, et al
    Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20885.
    PubMed     Abstract available


  446. MAEDA T, Hiura A, Uehara J, Toyoshima R, et al
    Early tumor response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20879.
    PubMed     Abstract available


  447. CHIESA Z
    How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20814.
    PubMed    


  448. BATAILLE V, Puig S
    COVID-19 vaccines and skin manifestations.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20807.
    PubMed    


  449. BEN ABDALLAH H, Vestergaard C
    Atopic dermatitis, hypertension and cardiovascular disease.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20802.
    PubMed    


  450. CAZZANIGA S, Naldi L
    Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20776.
    PubMed    


  451. CAMARA NOS
    Do the gut and skin microbiomes share thoughts on melanoma development?
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20811.
    PubMed    


  452. GAMBICHLER T, Krogias C, Tischoff I, Tannapfel A, et al
    Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20824.
    PubMed    


  453. PALLER AS, Tan JKL, Bagel J, Rossi AB, et al
    IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20872.
    PubMed     Abstract available


  454. LAMBERT WC, Sy CB, Madari AP, Schwartz RA, et al
    Perineal cutaneous basal cell carcinomas in patients with familial seronegative celiac disease: Report of three cases.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20870.
    PubMed     Abstract available


  455. SCHREUDER K, Hollestein L, Nijsten TEC, Wakkee M, et al
    A nationwide study of the incidence and trends of first and multiple basal cell carcinoma in the Netherlands and prediction of future incidence.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20871.
    PubMed     Abstract available


  456. KABASHIMA K, Matsumura T, Komazaki H, Kawashima M, et al
    Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20873.
    PubMed     Abstract available


  457. MAURUS K, Kosnopfel C, Kneitz H, Appenzeller S, et al
    Cutaneous epithelioid hemangiomas show somatic mutations in the MAPK pathway.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20869.
    PubMed     Abstract available


  458. SZABO A, Brodszky V, Rencz F
    A comparative study on the measurement properties of DLQI, DLQI-R and Skindex-16.
    Br J Dermatol. 2021 Nov 1. doi: 10.1111/bjd.20765.
    PubMed     Abstract available



  459. Patients who misuse alcohol have poorer responses to systemic treatments for psoriasis.
    Br J Dermatol. 2021;185:e179-e198.
    PubMed     Abstract available


  460. HWANG E, Tomayko MM
    COVID-19 outcomes in patients with autoimmune blistering disease.
    Br J Dermatol. 2021;185:1048-1050.
    PubMed    


  461. HSIAO J, Shi V
    Hidradenitis suppurativa: redirecting a life trajectory.
    Br J Dermatol. 2021;185:878.
    PubMed    


  462. ADOTAMA P, Callender V, Kolla A, Young C, et al
    Comparing the clinical differences in white and black women with frontal fibrosing alopecia.
    Br J Dermatol. 2021;185:1074-1076.
    PubMed    


  463. TEIXEIRA MS, Gavazzoni Dias MFR, Vilar EAG, Pantaleao L, et al
    Histopathological differential diagnosis of frontal fibrosing alopecia and fibrosing alopecia in a pattern distribution.
    Br J Dermatol. 2021;185:1069-1070.
    PubMed    


  464. SINIKUMPU SP, Vahanikkila H, Jokelainen J, Tasanen K, et al
    Male patients with rosacea have increased risk for migraine: a population-based study.
    Br J Dermatol. 2021;185:1058-1061.
    PubMed    


  465. PAPADAVID E, Kapniari E, Pappa V, Nikolaou V, et al
    Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity.
    Br J Dermatol. 2021;185:1035-1044.
    PubMed     Abstract available


  466. CHU CB, Yang CC, Tsai SJ
    Global data analysis supports smoking as the fundamental element associated with geographical sex disparities in hidradenitis suppurativa.
    Br J Dermatol. 2021;185:1054-1056.
    PubMed    


  467. CROITORU D, Sibbald C, Alavi A, Brooks S, et al
    Challenging the association of hepatitis C and pyoderma gangrenosum.
    Br J Dermatol. 2021;185:1047-1048.
    PubMed    


  468. MOYAL L, Arkin C, Gorovitz-Haris B, Querfeld C, et al
    Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
    Br J Dermatol. 2021;185:999-1012.
    PubMed     Abstract available


  469. HOWELLS L, Lancaster N, McPhee M, Bundy C, et al
    Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review.
    Br J Dermatol. 2021;185:921-934.
    PubMed     Abstract available


  470. LOFVENDAHL S, Norlin JM, Schmitt-Egenolf M
    Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study.
    Br J Dermatol. 2021;185:945-951.
    PubMed     Abstract available


  471. PRENS LM, Porter ML, Savage KT, Salian P, et al
    Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study.
    Br J Dermatol. 2021;185:1072-1074.
    PubMed    


    October 2021
  472. HOYER A, Rehbinder EM, Fardig M, Asad S, et al
    Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20831.
    PubMed     Abstract available


  473. VAN WINDEN MEC, Klosters FM, Hamaker M, Olde Rikkert MG, et al
    Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic.
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20833.
    PubMed     Abstract available


  474. GUTERMUTH J, Pink AE, Worm M, Soldbro L, et al
    Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo-controlled, randomized, Phase 3 clinical trial (ECZTRA 7).
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20832.
    PubMed     Abstract available


  475. OLIVER R, Krueger JG, Glatt S, Vajjah P, et al
    Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double-Blinded Study.
    Br J Dermatol. 2021 Oct 23. doi: 10.1111/bjd.20827.
    PubMed     Abstract available


  476. SBIDIAN E, Pina-Vegas L
    Head-to-head trials in psoriasis and psoriatic arthritis: how to conclude?
    Br J Dermatol. 2021 Oct 20. doi: 10.1111/bjd.20771.
    PubMed    


  477. GORDON KB, Lebwohl M, Papp KA, Bachelez H, et al
    Long-Term Safety of Risankizumab From 17 Clinical Trials in Patients With Moderate-to-Severe Plaque Psoriasis.
    Br J Dermatol. 2021 Oct 15. doi: 10.1111/bjd.20818.
    PubMed     Abstract available


  478. WOLLENBERG A, Beck LA, de Bruin Weller M, Simpson EL, et al
    Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
    Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20810.
    PubMed     Abstract available


  479. MONNET P, Herms F, Djermane M, Dalac S, et al
    Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors.
    Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20808.
    PubMed    


  480. HENDERSON BERG MH, Davison K, Popradi G
    Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20786.
    PubMed     Abstract available


  481. PUELLES J, Fofana F, Rodriguez D, Silverberg JI, et al
    Psychometric Validation and Responder Definition of Sleep Disturbance Numerical Rating Scale in Moderate-To-Severe Atopic Dermatitis.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20783.
    PubMed     Abstract available


  482. GOEBELER M, Bata-Csorgo Z, De Simone C, Didona B, et al
    Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open-label feasibility trial.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20782.
    PubMed     Abstract available


  483. EIGENTLER T
    Benefits of a nationwide population-based skin cancer screening programme - still a controversial debate.
    Br J Dermatol. 2021 Oct 4. doi: 10.1111/bjd.20709.
    PubMed    


  484. BERMINGHAM WH, Ardern-Jones MR, Huissoon AP, Krishna MT, et al
    Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.
    Br J Dermatol. 2021;185:838-839.
    PubMed    


  485. MURRELL DF, Patsatsi A, Stavropoulos P, Baum S, et al
    Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
    Br J Dermatol. 2021;185:745-755.
    PubMed     Abstract available


  486. SHOURICK J, Ahmed M, Seneschal J, Passeron T, et al
    Development of a shared decision-making tool in vitiligo: an international study.
    Br J Dermatol. 2021;185:787-796.
    PubMed     Abstract available


  487. HAW WY, Al-Janabi A, Arents BWM, Asfour L, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.
    Br J Dermatol. 2021;185:736-744.
    PubMed     Abstract available


    September 2021
  488. FROMME JE, Zigrino P
    Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor.
    Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20756.
    PubMed    


  489. CHONG BF
    Guidance for providers on the treatment and management of cutaneous lupus erythematosus.
    Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20746.
    PubMed    


  490. OH Y, Markova A, Noor SJ, Rotemberg V, et al
    Standardized Clinical Photography Considerations in Patients Across Skin Tones.
    Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20766.
    PubMed     Abstract available


  491. NAKAMURA T, Haider S, Fontanella S, Murray CS, et al
    Modelling trajectories of parentally reported and physician-confirmed atopic dermatitis in a birth cohort study.
    Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20767.
    PubMed     Abstract available


  492. COTTER C, Solman L, Flohr C
    A national audit of oral propranolol for the treatment of Infantile Hemangiomas.
    Br J Dermatol. 2021 Sep 2. doi: 10.1111/bjd.20738.
    PubMed     Abstract available


    July 2021
  493. PROCOPIO-AZEVEDO AC, Rabello VBS, Muniz MM, Figueiredo-Carvalho MHG, et al
    Hypersensitivity reactions in sporotrichosis: A retrospective cohort of 325 patients from a reference hospital in Rio de Janeiro, Brazil (2005-2018).
    Br J Dermatol. 2021 Jul 14. doi: 10.1111/bjd.20646.
    PubMed     Abstract available


    June 2021
  494. CARMIGNAC V, Salomon G, Severino-Freire M, Duffourd Y, et al
    Mosaic NEK9 mutation, fibrous dysplasia and premature puberty in nevus comedonicus syndrome.
    Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20603.
    PubMed     Abstract available


  495. BUI H, Skiba PN, Breskin A, Sayed C, et al
    Hidradenitis Suppurativa Among Patients with Human Immunodeficiency Virus: Investigating Patient and Disease Characteristics, and Misdiagnosis.
    Br J Dermatol. 2021 Jun 22. doi: 10.1111/bjd.20591.
    PubMed     Abstract available


    May 2021
  496. CLAESON M, Baade P, Marchetti M, Brown S, et al
    Comparative performance of predictors of death from thin (
    Br J Dermatol. 2021 May 12. doi: 10.1111/bjd.20480.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: